Zymeworks Launches $125 Million Share Buyback as Earnings Forecast Tightens

Biotechnology firm Zymeworks Inc. announced that its board has authorized a 2026 share repurchase program of up to $125 million, ending the 2025 program that bought back 4.2 million shares for $102.3 million at an average price of $24.36. The company had roughly 73 million shares outstanding on May 13, 2026 and the new buyback may be executed through open‑market transactions or other methods, subject to market conditions and regulatory limits, and can be suspended at any time.

Separately, equity research analyst R. Burns of HC Wainwright cut the company’s Q2 2026 earnings‑per‑share estimate to –$0.58 from –$0.29, while maintaining a “Buy” rating and a $51 price target. Zymeworks reported Q2 results on August 6, 2026 with a loss of $0.62 per share, missing the consensus forecast of –$0.57, and posted revenue of $4.59 million versus the $3.81 million expected. Other analysts have issued mixed ratings, ranging from strong‑buy to sell, with an average target price of $37.89.